[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Alignment Healthcare, Inc. (ALHC) filed a Form 144 notifying the proposed sale of 13,460,000 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $215,494,600.00. The filing lists the approximate sale date as 09/10/2025 and shows 198,031,417 shares outstanding, implying the proposed sale represents roughly 6.8% of outstanding shares. The securities were acquired on 09/16/2016 in a corporate reorganization involving Alignment Healthcare, Inc., and payment/consideration details reference remarks. No securities sales by the person in the past three months were reported.

Positive

• None.

Negative

• Large proposed sale: 13,460,000 shares representing approximately 6.8% of outstanding shares (198,031,417).
• High aggregate value: Proposed sale valued at $215,494,600.00, a material amount relative to typical single-transaction sizes.
• Concentrated execution: Sale is scheduled with Morgan Stanley & Co. LLC on or about 09/10/2025, which could affect near-term market liquidity.
• Limited contextual detail: Filing does not state whether the sale is under a pre-established trading plan (e.g., Rule 10b5-1) or provide additional mitigating context in Remarks.

Insights

Securities Analyst

TL;DR: Large proposed sale (~6.8% of outstanding shares) valued at $215.5M could be material to market supply.

The Form 144 discloses a substantial proposed block of 13,460,000 shares to be sold through Morgan Stanley with an aggregate market value of $215,494,600. Given the issuer's stated outstanding share count of 198,031,417, the position equals roughly 6.8% of shares outstanding, which is sizable relative to typical free-floating supply. The acquisition date is listed as 09/16/2016 via corporate reorganization, indicating these are not recent purchases. The filing does not provide any stop-loss or 10b5-1 plan details in the Remarks, and no sales in the prior three months are reported. This notice is material for investors because of its potential effect on share supply and near-term trading liquidity.

Corporate Governance Expert

TL;DR: An insider or related person plans a large disposition; disclosure is clear but raises governance and signaling questions.

The document identifies a planned sale of 13,460,000 shares through Morgan Stanley on or about 09/10/2025, with acquisition attributed to a 2016 corporate reorganization. The filer represents no undisclosed material adverse information. The filing lacks additional context such as whether the sale is pursuant to a pre-established trading plan or other constraints; such details would clarify governance safeguards. As presented, the filing is a material disclosure that stakeholders and governance committees will view as significant due to the volume relative to outstanding shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock, $0.001 par value per share	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	13460000	215494600.00	198031417	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock, $0.001 par value per share	09/16/2016	Corporate Reorganization	Alignment Healthcare, Inc.			13460000	09/16/2016	See Remarks

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Alignment Healthcare (ALHC) disclose?

The Form 144 discloses a proposed sale of 13,460,000 common shares via Morgan Stanley & Co. LLC with an aggregate market value of $215,494,600, approx. sale date 09/10/2025.

How large is the proposed sale relative to ALHC's outstanding shares?

The filing lists 198,031,417 shares outstanding; the proposed 13,460,000 shares equal roughly 6.8% of outstanding shares.

When and how were the securities to be sold acquired?

The securities were acquired on 09/16/2016 in a corporate reorganization, per the acquisition table in the filing.

Were any securities of ALHC sold by the same person in the past three months?

The filing reports: Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker is handling the proposed sale for ALHC's Form 144?

The named broker is Morgan Stanley & Co. LLC, located at 1585 Broadway, New York, NY 10036.